NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading PRPO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment is in a high-risk, loss-making company with a stable management team. The current thesis state is intact, but recent financial performance has shifted from mildly favorable to mixed, indicating potential volatility ahead.
The market appears to have priced in a low expectations gap, suggesting that PRPO is viewed as cheap compared to its peers. However, the valuation is justified, indicating that investors are cautious about the company's ability to improve its financials.
Management is focused on increasing revenue and achieving adjusted EBITDA profitability, which shows some positive momentum with revenue growth. However, operating income and net losses have been mixed, indicating that sustained improvement is still a challenge.
The future performance of PRPO hinges on the guidance provided in the next earnings call and the performance of sector bellwethers like TMO, DHR, and IDXX. If these companies continue to perform well, it could provide a favorable backdrop for PRPO, while any negative guidance could lead to further challenges.
Over the next 1 to 3 years, PRPO's trajectory will depend on its ability to manage risks and improve financial performance in a supportive sector environment. Not investment advice.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. The recent financial performance remains steady, and the reason to own it looks intact. There are no new threats or supports that would alter the current assessment.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will provide insights into financial health and future outlook.
Confirms one read:Earnings report shows a profit or positive guidance for future quarters.
Confirms the other:Earnings report reveals a loss or negative guidance for future quarters.
Why it matters: Earnings results will show if revenue growth continues and if losses improve. Investors will look for signs of progress.
Confirms one read:Earnings report shows revenue growth above 30% year over year and reduced net losses.
Confirms the other:Earnings report shows revenue growth below 20% year over year and increased net losses.
Why it matters: Revenue growth below the median would signal weakening demand in a growth sector.
Confirms:Q2 revenue growth reported below the median growth rate for the sector.
Disproves:Q2 revenue growth remains above the median growth rate for the sector.
Why it matters: If revenue growth picks up, it could signal a positive shift for Precipio in a maturing sector.
Confirms:Health Care sector revenue growth is speeding up to 12% year over year.
Disproves:Revenue growth remains below 9% year over year.
Why it matters: Keeping positive cash flow is key for the company's finances. It shows the company runs well.
Confirms:Cash flow from operations stays positive or gets better compared to last quarter.
Disproves:Cash flow from operations turns negative or declines from the previous quarter.
Why it matters: This call will provide insights on management's strategy and growth initiatives. It will be the first with a live Q&A.
Confirms one read:Management shares good news about revenue growth. They plan to cut net losses during the call.
Confirms the other:Management does not share clear plans for boosting revenue. They also lack plans to cut losses.
Why it matters: If management changes its plans, Precipio may not compete as well.
Confirms one read:Management shares a new plan to improve their market position.
Confirms the other:Management says there are no changes to the current plans or priorities.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
